Artículo Original 96 Lactobacillus strains. Laryngoscope 2008; 118: 599-604. 26.- Stewart DB, Hegarty JP. Correlation between virulence gene expression and proton pump inhibitors and ambient ph in Clostridium difficile: results of an in vitro study. J Med Microbiol 2013; 62: 1517-23. 27.- Leonard J, Marshall JK, Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102: 2047-56; quiz 2057. 28.- Bavishi C, Dupont HL. Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection. Alimentary Pharmacol Ther 2011; 34: 1269-81. 29.- Deshpande A, Pant C, Pasupuleti V, Rolston DD, Jain A, Deshpande N, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection in a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 225-33. 30.- Kwok CS, Arthur AK, Anibueze CI, Singh S, Cavallazzi R, Loke YK. Risk of Clostridium difficile infection with acid suppressing drugs and antibiotics: meta-analysis. Am J Gastroenterol 2012; 107: 1011-9. 31.- Janarthanan S, Ditah I, Adler DG, Ehrinpreis MN. Clostridium difficileassociated diarrhea and proton pump inhibitor therapy: a meta-analysis. Am J Gastroenterol 2012; 107: 1001-10. 32.- Tleyjeh IM, Bin Abdulhak AA, Riaz M, Alasmari FA, Garbati MA, Alghamdi M, et al. Association between proton pump inhibitor therapy and Clostridium difficile infection: a contemporary systematic review and meta-analysis. Plos One 2012; 7: e50836. 33.- Howell MD, Novack V, Grgurich P, Soulliard D, Novack L, Pencina M, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010; 170: 784-90. 34.- Freedberg DE, Salmasian H, Friedman C, Abrams JA. Proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol 2013; 108: 1794-801. 35.- Mcfarland LV, Surawicz CM, Rubin M, CONSENSO CHILENO DIARREA ASOCIADA A CLOSTRIDIUM DIFFICILE - C. Hernández-Rocha et al. Fekety R, Elmer GW, Greenberg RN. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999; 20: 43-50. 36.- Antharam VC, Li EC, Ishmael A, Sharma A, Mai V, Rand KH, et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013; 51: 2884-92. 37.- Fitzpatrick LR. Probiotics for the treatment of Clostridium difficile associated disease. World J Gastro Pathophysiol 2013; 4: 47-52. 38.- Hell M, Bernhofer C, Stalzer P, Kern JM, Claassen E. Probiotics in Clostridium difficile infection: reviewing the need for a multistrain probiotic. Benef Microbes 2013; 4: 39-51. 39.- Goldenberg JZ, Ma S S, Saxton JD, Martzen MR, Vandvik PO, Thorlund K, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. The Cochrane Database Syst Rev 2013; 5: CD006095. 40.- Johnston BC, Ma SS, Goldenberg JZ, Thorlund K, Vandvik PO, Loeb M, et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med 2012; 157: 878-88. 41.- Videlock EJ, Cremonini F. Metaanalysis: probiotics in antibioticassociated diarrhoea. Alimentary Pharmacol Ther 2012; 35: 1355-69. 42.- Johnson S, Maziade PJ, Mcfarland LV, Trick W, Donskey C, Currie B, et al. Is primary prevention of Clostridium difficile infection possible with specific probiotics? Int J Infect Dis 2012; 16: e786-92. 43.- Avadhani A, Miley H. Probiotics for prevention of antibiotic-associated diarrhea and Clostridium difficileassociated disease in hospitalized adults-a meta-analysis. J Am Acad Nurse Pract 2011; 23: 269-74. 44.- Allen SJ, Wareham K, Wang D, Bradley C, Hutchings H, Harris W, et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhoea and Clostridium difficile diarrhoea in older inpatients (PLACIDE): a randomised, double-blind, placebocontrolled, multicentre trial. Lancet 2013; 382: 1249-57. 45.- Mcfarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, et al. A randomized placebocontrolled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 1913-8. 46.- Surawicz CM, Elmer GW, Speelman P, Mcfarland LV, Chinn J, van Belle G. Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: a prospective study. Gastroenterol 1989; 96: 981-8. 47.- Pillai A, Nelson R. Probiotics for treatment of Clostridium difficileassociated colitis in adults. The Cochrane Database Syst Rev 2008: CD004611. 48.- Surawicz CM, Mcfarland LV, Greenberg RN, Rubin M, Fekety R, Mulligan ME, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 1012-7. 49.- Wullt M, Hagslatt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a doubleblind, placebo-controlled trial. Scand J Infect Dis 2003; 35: 365-7. 50.- Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005; 54: 905-6. 51.- Mcfarland LV. Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease. Am J Gastroenterol 2006; 101: 812-22. 52.- Mcfarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, et al. Prevention of beta-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 1995; 90: 439-48. 53.- Rautio M, Jousimies-Somer H, Kauma H, Pietarinen I, Saxelin M, Tynkkynen S, et al. Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus Gastroenterol. latinoam 2016; Vol 27, Nº 2: 79-100
gastro 2 2016
To see the actual publication please follow the link above